Oseltamivir effectiveness in seasonal influenza patients taking symptomatic therapy: retrospective analysis of RCT data.

Aims: The effectiveness of oseltamivir to improve seasonal influenza symptoms in clinical practice was analyzed using pooled data from patients who were also taking analgesics and other over-the-counter (OTC) medications.

Methods: Data were pooled from 1,709 patients aged 13 - 64 years with confirmed seasonal influenza who enrolled in six randomized, placebo-controlled trials of oseltamivir (75 mg b.i.

Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.

A 2008 review by our group concluded that the risk of neuropsychiatric adverse events (NPAEs) in influenza patients was not increased by oseltamivir exposure, and did not identify any mechanism by which oseltamivir or its metabolites could cause or worsen such events. The current article reviews new information on this topic. Between September 16, 2007 and May 15, 2010, 1,805 spontaneously-reported NPAEs were identified in 1,330 patients receiving oseltamivir: 767 (42.

Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients.

Background: Haematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients are at high risk for severe influenza and its complications, and may not be adequately protected by vaccination.

Methods: Liver, kidney, or liver-kidney transplant or allogeneic HSCT recipients aged ≥1 year were randomized to oseltamivir (75 mg once daily for those ≥13 years or weight-based dosing for children 1-12 years) or placebo for 12 weeks during periods of local influenza circulation. Patients were assessed for influenza infection via daily diary, every-other-week culture and PCR, and baseline and end-of-treatment serology.